Aldeyra Therapeutics, Inc. (ALDX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$65.0M
Cash & Equivalents
$5.1M
Quarterly Burn Rate
38 mo
Est. Cash Runway
$125M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase3 Readout | — |
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07402876 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | PHASE3 | Recruiting | 20 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-10 | 8-K | Aldeyra Therapeutics, Inc. (ALDX) (CIK 0001341235) - EX-99.1 | EDGAR |